DNA nanotechnology-based development of delivery systems for bioactive compounds. by Mohri, Kohta et al.
Title DNA nanotechnology-based development of delivery systemsfor bioactive compounds.
Author(s)Mohri, Kohta; Nishikawa, Makiya; Takahashi, Yuki; Takakura,Yoshinobu
Citation
European journal of pharmaceutical sciences : official journal








DNA nanotechnology-based development of delivery systems for 
bioactive compounds 
 




Department of Biopharmaceutics and Drug Metabolism, Graduate School of 
Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan 
 
Abstract 
Nucleic acids, DNA and RNA, not only allow transfer and replication of densely coded 
genetic information, but also act as danger signals triggering innate immune response. 
Recent progress in the design and construction of nano-sized structures using DNA has 
opened a new field of nanotechnology. The unique properties of nano-sized DNA 
constructs can be exploited to develop programmable materials for efficient delivery of 
bioactive compounds. In this review, recent advances in DNA nanotechnology and its 
applications as delivery systems are summarized. In particular, we focus on the delivery 
of DNA containing unmethylated cytosine-phosphate-guanine (CpG) dinucleotide, or 
CpG motif, to immune cells expressing Toll-like receptor 9. Recent studies have shown 
that precisely designed DNA constructs, such as multi-branched DNA, polyhedral DNA, 
and DNA origami, can be used to enhance the biological activity of CpG DNA. 
 











For millions of years, living organisms have used nucleic acids, DNA and RNA, 
to encode, transfer, decode, and transcribe genetic information. This is largely attributed 
to the nature of the nucleic acids to form a double-stranded structures with a 
complementary strand (Watson and Crick, 1974), and the double-strand formation keeps 
the genetic information unchanged (Crick, 1970). Recently, this ability to form 
double-stranded structures has been exploited to construct a variety of unnatural tertiary 
DNA structures—DNA-based nano-scale materials. To date, DNA nanotechnology has 
been used in optical detection, diagnostics, and drug delivery (Seeman, 2010; Roh et al., 
2011b; Hartman et al., 2013). 
 From a structural perspective, there are many advantages of using DNA as a 
building block for developing diagnostic and therapeutic materials. The classical 
right-handed double helical DNA, B-DNA, is a nano-scale species; the diameter and 
helical rise of B-DNA is about 2 nm and 0.34 nm/base, respectively (Leslie et al., 1980). 
Two DNA molecules can be ligated to form one species via DNA ligase-catalyzed 
reactions (Figure 1A). Single-stranded overhangs, called sticky ends, are used for the 
ligation of DNA molecules (Wu and Wallace, 1989). This permits the 
custom-fabrication of readily programmable intermolecular connections and allows us 
to synthesize desired DNA structures with varying functions (Lee et al., 2009). 
Branched DNA with junction points has also been used as building blocks. A typical 
branched DNA forms a four-armed Holliday junction, an intermediate structure formed 
during the process of genetic recombination (Holliday, 1964; Shinagawa and Iwasaki, 
1995). In addition, Y-shaped (Y-DNA) and X-shaped (X-DNA) DNAs have been 
designed and synthesized using three or four oligodeoxynucleotides (ODNs), 
respectively, with the halves of each ODN being partially complementary to a half of 
each of the other two ODNs (Kallenbach et al., 1983; Ma et al., 1986) (Figure 1B). The 
branched DNA can be used to create two- or three-dimensional networked structures 
(Seeman, 1982).  
 These approaches enable us to develop several types of self-assembled and 
bottom-up tertiary DNA structures. DNA is a highly homogeneous and inexpensive 
material which can be obtained by total synthesis. In addition, DNA is a chemically 
stable molecule. Chemical modification of the functional groups of DNA can also be 
possible. These properties of DNA are the advantages of DNA-based delivery systems. 
 Recent studies have found that DNA nanostructures are useful for pharmaceutical 
and biomedical applications (Nishikawa et al., 2010). DNA or RNA containing specific 
sequences, such as antisense ODN, decoy ODN, small interfering RNA (siRNA), and 
unmethylated cytosine-phosphate-guanine (CpG) ODN, has several biological functions, 
including the inhibition of expression of target molecules and the activation of innate 
immunity (Dove, 2002; Fattal and Bochot, 2006; Krishnamachari and Salem, 2009; 
Tomita et al., 2003). DNA nanostructures constructed using functional nucleic acids 
could improve or strengthen their biological activity. Nucleic acids are degraded by 
nucleases in vivo (Takakura et al., 2001). This biodegradability assures that DNA and 
RNA are biocompatible. Therefore, oligomers and polymers consisting of DNA can be 
used for the development of biodegradable, biocompatible, and safe nano-scale 
materials. In this review, approaches to use nano-scale DNA structures exhibiting 
unique structural properties as drug delivery systems (DDS) are summarized. 
 
2. DNA nanostructures for drug delivery systems 
Pioneering work by Seeman and coworker, who constructed a DNA cube, laid the 
foundation for DNA nanotechnology (Chen and Seeman, 1991). Since then, a number of 
self-assembled polyhedral DNA nanostructures have been developed (He et al., 2008, 
2010; Zhang et al., 2008, 2009, 2010; Li et al., 2012) (Figure 1C). 
A group of researchers from Cornell University developed dendrimer-like DNA 
(DL-DNA) through the ligation of Y-DNA building blocks (Li et al., 2004; Freedman et 
al., 2005). Three ODNs with the halves of each ODN being complementary to a half of 
the other two ODNs are used to construct Y-DNA, and which are ligated to each other 
through the adhesive terminal ends using T4 DNA ligase. The numerous terminals of 
the DL-DNA can be used to conjugate any functional moieties, including fluorescent 
probes. Rothemund (2006) prepared materials of arbitrary two-dimensional shapes, 
including a smiley face, using a 7-kilobase single-stranded scaffold and over 200 short 
‘staple strands’ to hold the scaffold in place. The multiple staple strands were hybridized 
to the long scaffold strand by simple annealing. This method, known as “DNA origami”, 
allows the arrangement of a large number of ODNs with nano- to micrometer precision 
and made it possible to create more complex and larger structures. The DNA 
nanostructures developed thus far have shown enormous potential for applications in a 
number of fields. 
 Synthetic or semi-synthetic DNA or RNA has the potential to interact with target 
molecules, such as endogenous DNA, RNA, and proteins. Such nucleic acids can be 
used as therapeutic agents for the treatment of diseases. Because there are several 
barriers for the delivery of functional DNA and RNA, a variety of delivery systems, 
including liposomes, nanoparticles, polymers, and molecular conjugates, have been 
developed (Ma et al., 2005; Lee et al., 2012; Tsai et al., 2012; Lambert et al., 2001). 
Although cationic liposomes and polymers are frequently used for the delivery of 
nucleic acid drugs, there is a concern that such compounds could cause damages to the 
cell membrane. Hydrogels have been used for the encapsulation and sustained release of 
drugs (Nayak and Lyon, 2005). However, most hydrogels are prepared by 
polymerization and may contribute to DNA damage and cytotoxicity. Biodegradable 
hydrogels made of natural polymers, including gelatin and hyaluronic acid, generally 
lack homogeneity.  
 DNA nanotechnology-based methods would solve the problems associated with 
the delivery of nucleic acid drugs. Several examples are summarized in Table 1. Keum 
et al. (2011) reported that compared with their linear counterparts, tetrahedral DNA 
containing an antisense motif showed higher efficiency in inhibiting the expression of 
enhanced green fluorescent protein (EGFP) in cultured cells. Lee et al. (2012) 
developed tetrahedral DNA-nanoparticles of defined size and succeeded in delivering 
siRNAs into cancer cells, where they silenced the expression of target genes. 
Modification of the tetrahedral DNA with folic acid greatly enhanced the efficiency of 
RNA interference in folate receptor-positive cancer cells. The size of the tetrahedral 
DNA-nanoparticle was about 30 nm and this property led to a longer circulation time of 
the nanoparticles (t1/2 ≈ 24.2 min) than that of the parent siRNA (t1/2 ≈ 6 min). 
 Roh et al. (2011a) developed DNAsome, a liposome-like vesicle consisting of 
lipid-conjugated Y-DNA. Its amphiphilic nature allowed the lipid-conjugated Y-DNA to 
self-assemble and form submicron particles. These authors showed that the delivery of 
siRNA targeting the anti-apoptotic gene Bcl-2 can be achieved by using DNAsomes. 
Further, the authors also showed that the delivery of the siRNA together with 
doxorubicin (DXR), an anti-cancer-agent, to cancer cells inhibited their proliferation. 
Um et al. (2006) developed DNA hydrogels by ligating Y-DNA, the X-shaped DNA 
(X-DNA), or T-shaped DNA. The authors reported that macromolecular drugs like 
insulin can be loaded into and gradually released from these hydrogels. More recently, a 
meta-hydrogel that has the ability to restore its original shape has also been created with 
DNA by employing a rolling circle amplification method (Lee et al., 2012). 
 Jiang et al. (2012) reported that a DNA nanostructure prepared using the DNA 
origami technology delivered DXR that was intercalated into the structure and inhibited 
the proliferation of not only MCF-7 human breast adenocarcinoma cells, but also that of 
doxorubicin-resistant cells. Zhao et al. (2012) developed two DNA origami-based 
nanostructures to deliver DXR into three different breast cancer cell lines 
(MDA-MB-231, MDA-MB-468, and MCF-7) and successfully induced programmed 
cell death. Using DNA origami method, Andersen et al. (2009) created a 
three-dimensional addressable DNA box that can be opened by an externally supplied 
DNA ‘key’. Douglas et al. (2012) developed an aptamer-gated hexagonal barrel 
nanostructure. The nanostructure loaded with antibody fragments was used to trigger 
cell-signaling in cultured cells. These antibodies bound to cell surface receptors and 
inhibited the cell growth. 
 
3. DNA-mediated stimulation of innate immunity 
Mammalian innate immune system recognizes damage-associated molecular 
patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs) as danger 
signals. Several DNA or RNA sensors have recently been identified in mammalian cells 
(Ozinsky et al., 2000). The recognition of nucleic acids by these sensors produces type I 
interferons (IFNs) and proinﬂammatory cytokines and upregulates the expression of 
costimulatory molecules (Figure 2). These responses could be used in the treatment of 
some diseases (Ishii and Akira, 2007). 
 
3.1. DNA/RNA sensors 
Toll-like receptors (TLRs) play essential roles in the activation of innate immune 
responses through the recognition of PAMPs expressed on a wide array of microbes and 
endogenous DAMPs released from stressed or dying cells (Adams, 2009; Matzinger, 
1994; Rakoff-Nahoum et al., 2004). TLR3, TLR7/8, or TLR9 recognizes exogenous or 
endogenous RNA/DNA in endosomal vesicles (Kawai and Akira, 2006). Viral, bacterial, 
and mammalian DNAs binds to TLR9, but microbial DNA is more efficient in 
activating the innate immune system compared with self DNA (Krieg, 2002). This is 
because, bacterial and viral DNAs harbor CpG motifs with much higher frequency 
compared with mammalian DNA (Bird, 1987). Bacterial and viral DNAs contain many 
CpG motifs, which is unmethylated cytosine-phosphate-guanine dinucleotides, whereas 
CG dinucleotides in mammalian DNA is highly methylated at the C5 position of 
cytosine. Thus, TLR9 is a receptor for microbial DNA containing CpG motifs (CpG 
DNA) but does not recognize methylated CpG dinucleotides in mammalian DNA 
(Tokunaga et al., 1988). TLR9 ligation recruits myeloid differentiation primary response 
protein 88 (MyD88) and activates downstream signaling pathways (Kawai et al., 2004). 
The activated TLR9-positive cells, including dendritic cells and macrophages, secrete 
proinflammatory cytokines and type I IFNs (Uematsu and Akira, 2007). Because 
double-stranded RNA and single-stranded RNA, respectively, are the ligands of TLR3 
and TLR7/8, bacterial and viral RNAs are recognized by these TLRs, and induce the 
production of type I IFNs (Kawai and Akira, 2006). 
 Other DNA sensors identified include DNA-dependent activator of IRFs (DAI) 
and Z-DNA binding protein 1 (ZBP1) (Takaoka et al., 2007; Wang et al., 2008). DAI 
interacts directly with double-stranded DNA in the cytoplasm and is capable of 
activating interferon regulatory factor 3 (IRF3), leading to the production of type-I IFNs. 
Several cytosolic RNA sensors, including retinoic acid-inducible gene I (RIG-I), 
melanoma differentiation-associated gene 5 (MDA5), and probable ATP-dependent 
RNA helicase DHX58 (or laboratory of genetics and physiology-2; LGP2), have been 
identified (Swiecki et al., 2011). A cytosolic helicase, RIG-I is a key sensor of viral 
infection and is activated by single-stranded triphosphate RNA, which stimulates the 
secretion of IFN- and IFN- from monocytes (Hornung et al., 2006; Schlee et al. 
2009). Therefore, the activation of the innate immune system following the recognition 
of viral and synthetic RNA containing 5-triphosphate by RIG-I can be useful for the 
immunotherapy of cancer. Poeck et al. (2008) reported that Bcl2-specific siRNA 
containing 5-triphosphate (3p-siRNA) potently inhibited the growth of melanoma. It is 
interesting that the recognition of 3p-siRNA by RIG-I synergized with siRNA-mediated 
Bcl2 silencing to induce massive apoptosis of cancer cells. 
 
3.2 Therapeutic application of CpG DNA 
As mentioned above, CpG DNA is a ligand for TLR9 and triggers innate immune 
response. Therefore, CpG DNA can be used as a therapeutic agent or an adjuvant for the 
treatment of a wide range of diseases, including cancer, viral infection, and allergies 
(Smyth et al., 2000; Baron et al., 1991). However, natural CpG DNA has some 
drawbacks as a therapeutic agent—the natural, phosphodiester (PO) DNA or ODN is 
prone to enzymatic degradation, has short in vivo circulation time, and has a low 
membrane permeability (Emlen and Mannik, 1984; Sands et al., 1994). To overcome 
these obstacles, cationic liposomes and polymers have been used to deliver CpG DNA 
into TLR9-positive cells (Kuramoto et al., 2006; Smolarczyk et al., 2005). Additionally, 
a variety of chemically modified DNA analogs, including phosphorothioate (PS) ODN, 
2-O-methyl ODN, morpholinos, methylphosphonate ODN, phosphoramidate ODN, and 
locked nucleic acid, have been developed for achieving enhanced stability against 
nucleases (Wagner, 1994; Crooke, 2004a, 2004b; Grünweller et al., 2003). In particular, 
PS ODN that can be synthesized by simple methods is widely used in studies involving 
CpG DNA because of their resistance to enzymatic degradation (Stein et al., 1988). 
However, PS ODN binds serum proteins and cellular membranes with high affinity 
(Brown et al., 1994; Monteith et al., 1999). It was reported that PS-ODNs accumulate in 
the kidney and induce renal toxicity, including renal proximal tubular degeneration at 
high doses (Monteith et al., 1999). 
 The flanking sequence preferences of CpG motif have been extensively studied 
(Lenert et al., 2006; Rankin et al., 2001). The optimal flanking sequences for rodent and 
human TLR9 respectively are 5-GACGTT-3 and 5-GTCGTT-3 (Rankin et al., 2001; 
Yi et al., 1998). CpG DNA has been categorized into four classes: class A (also known 
as type D), class B (also known type K), class C, and class P. Class A CpG DNA that 
contains a palindrome sequence for spontaneous G-tetrad formation, forms nano-sized 
oligomers under physiological conditions, and induces massive secretion of type I IFNs 
from plasmacytoid dendritic cells (pDCs) (Kerkmann et al., 2005). In contrast, class B 
CpG DNA is a linear molecule and has little potency to induce the production of type I 
IFNs (Krug et al., 2001), but is a potent mitogenic signal for human B cells and induces 
the secretion of large amounts of proinflammatory cytokines (Brown et al., 1998; Yi et 
al., 1996). It is interesting that polystyrene nanoparticle loaded with class B CpG DNA, 
which is similar in size as the oligomers of class A CpG DNA, shows enhanced potency 
to induce IFN- (Kerkmann et al., 2005). This indicates that the immune responses 
depend on the tertiary structures of CpG DNA. Class C CpG DNA stimulates the 
production of moderate levels of type I IFNs in pDCs and directly activates B cells 
(Poeck et al., 2004; Hartmann et al., 2003; Marshall et al., 2003; Vollmer et al., 2004). 
 
4. DNA assemblies for the delivery of CpG DNA 
Recent studies have reported that a variety of DNA-based nanostructures increase 
the biological activity of CpG DNA. Figure 3 summarizes the DNA assemblies that 
have been used for the delivery of CpG DNA. Soluble DNA nanostructures, including 
dumbbell shaped DNA, polypod-like DNA (polypodna), and dendrimer-like DNA 
(DL-DNA), are used for the targeted delivery of CpG DNA to TLR9-positive cells, such 
as dendritic cells, whereas DNA hydrogel is a formulation for sustained release of the 
immunostimulatory DNA. In this section, recent challenges in the delivery of CpG 
DNA using DNA nano-assemblies are summarized. 
 
4.1. Dumbbell shaped DNA 
Once administered, the short DNA, including CpG DNA, is quickly degraded by 
DNases in blood or other biological fluids (Goodchild et al., 1991). It has been reported 
that loop formation increases the stability of short double-stranded DNA by making its 
terminals unavailable to exonucleases (Chu et and Orgel, 1992; Clusel et al., 1993). 
Schmidt et al. (2006) designed a dumbbell-like covalently-closed PO CpG DNA 
(dSLIM-30L1) to increase the resistance to enzymatic degradation. The dSLIM-30L1 
was effective in inducing the production of proinflammatory cytokines, including 
interleukin (IL)-2 and IL-12p40. Further, its activity was comparable to that of a linear 
CpG DNA that contained phosphorothioate backbones at both ends. Yang et al. (2013) 
reported that CpG DNA with double stem-loop structure stimulated the proliferation of 
human peripheral blood mononuclear cells (PBMCs) and inhibited the growth of breast 
cancer in mice. 
 
4.2. Branched, polypod-like structured DNA 
Branched DNA is used as a building block for the construction of tertiary DNA 
structures because the branches can be used for connecting new DNA units. Y-DNA has 
a simple branched structure, and it is prepared using three ODNs with the halves of each 
ODN being partially complementary to the halves of the other two ODNs (Nishikawa et 
al., 2008; Matsuoka et al., 2010). Nishikawa et al. (2008) have previously reported that, 
compared to their single-stranded counterparts, Y-DNA containing three potent CpG 
motifs induces the secretion of significantly higher levels of tumor necrosis factor- and 
interleukin-6 from RAW264.7 macrophage-like cells. The enhanced immunostimulatory 
activity of Y-DNA was associated with increased cellular uptake by TLR9-positive cells. 
Subsequently, Mohri et al. (2012a) designed and developed nano-sized, polypod-like 
DNA (polypodna) containing CpG motifs (Figure 3A). Polypodna preparations 
consisting of three to eight 36-mer ODNs were successfully obtained by simple 
annealing. All polypodnas induced the secretion of large amounts of cytokines from 
macrophage-like RAW264.7 cells. Mohri et al. (2012a) found that increasing the 
number of pods increased the cellular uptake, but reduced the biological stability. Loop 
formation at the terminals of tetrapodna increased the stability in mouse serum and led 
to higher immunostimulatory activity than tetrapodna without loops (Mohri et al., 
2012b). High activity of the polypodna preparations were also observed after addition to 
human PBMCs (Uno et al., in press). 
 
4.3. Dendrimer-like DNA and DNA hydrogel 
Ligation of several polypodnas with overhangs at the 5-ends using T4 DNA 
ligase results in the formation of DL-DNA (Figure 3B). Rattanakiat et al., (2009) have 
developed the second and third generations of DL-DNA containing respectively 12 or 
24 highly potent CpG motifs in one unit. These DL-DNAs exhibit significantly high 
immunostimulatory activity compared with their individual components, including the 
CpG motif-containing tripodna. Further, a DNA hydrogel was also prepared by the 
ligation of polypodna with overhangs at all of the 5-ends of a palindromic sequence 
(Um et al., 2006). Nishikawa et al., (2011) developed DNA hydrogel with 
immunostimulatory CpG DNA by connecting tetrapodna preparations (Figure 3C). The 
CpG DNA hydrogel induced cytokine release from immune cells and gradually released 
DXR. Administration of CpG DNA hydrogel containing DXR effectively inhibited the 
growth of colon 26 tumor in mice. 
 
4.4. Tetrahedron DNA 
Goodman and coworkers developed a method for single-step synthesis of a 
tetrahedral DNA nanostructure (Goodman et al., 2004). Li et al. (2011) designed and 
prepared functional, multivalent DNA nanostructures by appending CpG DNA to 
tetrahedral DNA. The tetrahedral DNA with CpG motifs was efficiently taken up by 
TLR9-positive cells and activated the downstream pathways to induce the secretion of 
various proinﬂammatory cytokines at high concentrations. The stability of tetrahedral 
DNA nanostructure was higher than that of double-stranded DNA in fetal bovine serum 
and in cells. Liu et al. (2012) used CpG DNA-containing tetrahedral DNA nanostructure 
as a vehicle for the delivery of streptavidin, a model antigen. The precisely designed 
nano-sized complexes induced strong and long-lasting antigen-specific responses in 
mice without stimulating reaction to the DNA nanostructure itself, indicating that 
tetrahedral DNA has the potential to serve as a general platform for vaccine delivery. 
 
4.5. DNA origami tube 
The DNA origami technique has also been used to synthesize complex DNA 
structures (Castro et al., 2011). Some DNA origami-based assemblies can be used as 
scaffolds for chemical and biological processes (Simmel, 2012). The structural patterns 
of DNA origami technique-based tubes are programmable (Castro et al., 2011). Further, 
the surface of the DNA tube can be modified with a wide variety of biomolecules, 
including proteins and nucleic acids. Such modification could extend the use of DNA 
tubes into biomedical applications. Schüller et al. (2011) developed a tube-shaped DNA 
origami structure consisting of 30 parallel double-helices that were covered with 62 
CpG ODNs. This DNA origami tube triggered a strong immune response as 
characterized by cytokine production and activation of freshly isolated spleen cells. 
 
5. Conclusion 
The field of DNA technology is rapidly growing with the realization that DNA 
can be useful as a generic material. In this review, we summarized the recent advances 
in the development of DNA nanotechnology-based systems consisting of self-assembled 
DNA nanostructures. Since these DNA structures can be freely designed and are 
programmable, their structural properties can be and should be tuned for specific 
applications. Available information clearly suggests that DNA nanostructures offer 
promising new avenues for the delivery of immunostimulatory nucleic acids to immune 
cells expressing their receptors. We believe that precisely designed DNA nanostructures 





Adams, S., 2009. Toll-like receptor agonists in cancer therapy. Immunotherapy 1, 
949-964. 
Andersen, E.S., Dong, M., Nielsen, M.M., Jahn, K., Subramani, R., Mamdouh, W., 
Golas, M.M., Sander, B., Stark, H., Oliveira, C.L., Pedersen, J.S., Birkedal, V., 
Besenbacher, F., Gothelf, K.V., Kjems, J., 2009. Self-assembly of a nanoscale DNA 
box with a controllable lid. Nature 459, 73-76.  
Baron, S., Tyring, S.K., Fleischmann, Jr. W.R., Coppenhaver, D.H., Niesel, D.W., 
Klimpel, G.R., Stanton, G.J., Hughes, T.K., 1991. The interferons. Mechanisms of 
action and clinical applications. JAMA 266, 1375-1383. 
Bird, A.P., 1987. CpG islands as gene markers in the vertebrate nucleus. Trends Genet 3, 
342-347. 
Brown, D.A., Kang, S.H., Gryaznov, S.M., DeDionisio, L., Heidenreich, O., Sullivan, S., 
Xu, X., Nerenberg, M.I., 1994. Effect of phosphorothioate modification of 
oligodeoxynucleotides on specific protein binding. J. Biol. Chem. 269, 
26801-26805. 
Brown, W.C., Estes, D.M., Chantler, S.E., Kegerreis, K.A., Suarez, C.E., 1998. DNA 
and a CpG oligonucleotide derived from Babesia bovis are mitogenic for bovine B 
cells. Infect. Immun. 66, 5423-5432. 
Castro, C.E., Kilchherr, F., Kim, D.N., Shiao, E.L., Wauer, T., Wortmann, P., Bathe, M., 
Dietz, H., 2011. A primer to scaffolded DNA origami. Nat. Methods. 8, 221-229. 
Chen, J.H., Seeman, N.C., 1991. Synthesis from DNA of a molecule with the 
connectivity of a cube. Nature 350, 631-633. 
Chu, B.C., Orgel, L.E., 1992. The stability of different forms of double-stranded decoy 
DNA in serum and nuclear extracts. Nucleic Acids Res. 20, 5857-5858. 
Clusel, C., Ugarte, E., Enjolras, N., Vasseur, M., Blumenfeld, M., 1993. Ex vivo 
regulation of speciﬁc gene expression by nanomolar concentration of 
double-stranded dumbbell oligonucleotides. Nucleic Acids Res. 21, 3405-3411. 
Crick, F., 1970. Central dogma of molecular biology. 227, 561-563. 
Crooke, S.T., 2004a. Antisense strategies. Curr. Mol. Med. 4, 465-487. 
Crooke, S.T., 2004b. Progress in antisense technology. Annu. Rev. Med. 55, 61-95. 
Douglas, S.M., Bachelet, I., Church, G.M., 2012. A logic-gated nanorobot for targeted 
transport of molecular payloads. Science 335, 831-834.  
Dove, A., 2002. Antisense and sensibility. Nat. Biotechnol. 20, 121-124. 
Emlen, W., Mannik, M., 1984. Effect of DNA size and strandedness on the in vivo 
clearance and organ localization of DNA. Clin. Exp. Immunol. 56, 185-192. 
Fattal, E., Bochot, A., 2006. Ocular delivery of nucleic acids: antisense oligonucleotides, 
aptamers and siRNA. Adv. Drug Deliv. Rev. 58, 1203-1223. 
Freedman, K.O., Lee, J., Li, Y., Luo, D., Skobeleva, V.B., Ke, P.C., 2005. Diffusion of 
single star-branched dendrimer-like DNA. J. Phys. Chem. B. 109, 9839-9842. 
Goodchild, J., Kim, B., Zamecnik, P.C., 1991. The clearance and degradation of 
oligodeoxynucleotides following intravenous injection into rabbits. Antisense Res. 
Dev. 1, 153-60. 
Goodman, R.P., Berry, R.M., Turberfield, A.J., 2004. The single-step synthesis of a 
DNA tetrahedron. Chem. Commun. 1372-1373. 
Grünweller, A., Wyszko, E., Bieber, B., Jahnel, R., Erdmann, V.A., Kurreck, J., 2003. 
Comparison of different antisense strategies in mammalian cells using locked 
nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA. 
Nucleic Acids Res. 31, 3185-3193. 
Hartman, M.R., Ruiz, R.C., Hamada, S., Xu, C., Yancey, K.G., Yu, Y., Han, W., Luo, D., 
2013. Point-of-care nucleic acid detection using nanotechnology. Nanoscale. 5, 
10141-10154. 
Hartmann, G., Battiany, J., Poeck, H., Wagner, M., Kerkmann, M., Lubenow, N., 
Rothenfusser, S., Endres, S., 2003. Rational design of new CpG oligonucleotides 
that combine B cell activation with high IFN-alpha induction in plasmacytoid 
dendritic cells. Eur. J. Immunol. 33, 1633-1641. 
He, Y., Su, M., Fang, P.A., Zhang, C., Ribbe, A.E., Jiang, W., Mao, C., 2010. On the 
chirality of self-assembled DNA octahedra. Angew. Chem., Int. Ed. 49, 748-751. 
He, Y., Ye, T., Su, M., Zhang, C., Ribbe, A.E., Jiang, W., Mao, C., 2008. Hierarchical 
self-assembly of DNA into symmetric supramolecular polyhedral. Nature 452, 
198-201. 
Holliday, R., 1964. A mechanism for gene conversion in fungi. Genet. Res. 5, 282-304. 
Hornung, V., Ellegast, J., Kim, S., Brzózka, K., Jung, A., Kato, H., Poeck, H., Akira, S., 
Conzelmann, K.K., Schlee, M., Endres, S., Hartmann, G., 2006. 5'-Triphosphate 
RNA is the ligand for RIG-I. Science 314, 994-997. 
Ishii, K.J., Akira, S., 2007. Toll or toll-free adjuvant path toward the optimal vaccine 
development. J. Clin. Immunol. 27, 363-371. 
Jiang, Q., Song, C., Nangreave, J., Liu, X., Lin, L., Qiu, D., Wang, Z.G., Zou, G., Liang, 
X., Yan, H., Ding, B., 2012. DNA origami as a carrier for circumvention of drug 
resistance. J. Am. Chem. Soc. 134, 13396-133403.  
Kallenbach, N.R., Ma, R.I., Seeman, N.C., 1983. An immobile nucleic acid junction 
constructed from oligonucleotides. Nature 305, 829-831. 
Kawai, T., Akira, S., 2006. Innate immune recognition of viral infection. Nat. Immunol. 
7, 131-137. 
Kawai, T., Sato, S., Ishii, K.J., Coban, C., Hemmi, H., Yamamoto, M., Terai, K., 
Matsuda, M., Inoue, J., Uematsu, S., Takeuchi, O., Akira, S., 2004. Interferon-alpha 
induction through Toll-like receptors involves a direct interaction of IRF7 with 
MyD88 and TRAF6. Nat. Immunol. 5, 1061-1068. 
Kerkmann, M., Costa, L.T., Richter, C., Rothenfusser, S., Battiany, J., Hornung, V., 
Johnson, J., Englert, S., Ketterer, T., Heckl, W., Thalhammer, S., Endres, S., 
Hartmann, G., 2005. Spontaneous formation of nucleic acid-based nanoparticles is 
responsible for high interferon-alpha induction by CpG-A in plasmacytoid dendritic 
cells. J. Biol. Chem. 280, 8086-8093. 
Keum, J.W., Ahn, J.H., Bermudez, H., 2011. Design, assembly, and activity of antisense 
DNA nanostructures. Small 7, 3529-3535.  
Krieg, A.M., 2002. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. 
Immunol. 20, 709-760. 
Krishnamachari, Y., Salem, A.K., 2009. Innovative strategies for co-delivering antigens 
and CpG oligonucleotides. Adv. Drug Deliv. Rev. 61, 205-217. 
Krug, A., Rothenfusser, S., Hornung, V., Jahrsdorfer, B., Blackwell, S., Ballas, Z.K., 
Endres, S., Krieg, A.M., Hartmann, G., 2001. Identification of CpG oligonucleotide 
sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur. 
J. Immunol. 31, 2154-2163. 
Kuramoto, Y., Nishikawa, M., Hyoudou, K., Yamashita, F., Hashida, M., 2006. 
Inhibition of peritoneal dissemination of tumor cells by single dosing of 
phosphodiester CpG oligonucleotide/cationic liposome complex. J. Control. Release. 
115, 226-233. 
Lambert, G., Fattal, E., Couvreur, P., 2001. Nanoparticulate systems for the delivery of 
antisense oligonucleotides. Adv. Drug Deliv. Rev. 47, 99-112. 
Lee, H., Lytton-Jean, A.K., Chen, Y., Love, K.T., Park, A.I., Karagiannis, E.D., Sehgal, 
A., Querbes, W., Zurenko, C.S., Jayaraman, M., Peng, C.G., Charisse, K., 
Borodovsky, A., Manoharan, M., Donahoe, J.S., Truelove, J., Nahrendorf, M., 
Langer, R., Anderson, D.G., 2012. Molecularly self-assembled nucleic acid 
nanoparticles for targeted in vivo siRNA delivery. Nat. Nanotechnol. 7, 389-393.  
Lee, J.B., Peng, S., Yang, D., Roh, Y.H., Funabashi, H., Park, N., Rice, E.J., Chen, L., 
Long, R., Wu, M., Luo, D., 2012. A mechanical metamaterial made from a DNA 
hydrogel. Nat. Nanotechnol. 7, 816-820.  
Lee, J.B., Roh, Y.H., Um, S.H., Funabashi, H., Cheng, W., Cha, J.J., Kiatwuthinon, P., 
Muller, D.A., Luo, D., 2009. Multifunctional nanoarchitectures from DNA-based 
ABC monomers. Nat. Nanotechnol. 4, 430-436. 
Lee, S.J., Huh, M.S., Lee, S.Y., Min, S., Lee, S., Koo, H., Chu, J.U., Lee, K.E., Jeon, H., 
Choi, Y., Choi, K., Byun, Y., Jeong, S.Y., Park, K., Kim, K., Kwon, I.C., 2012. 
Tumor-homing poly-siRNA/glycol chitosan self-cross-linked nanoparticles for 
systemic siRNA delivery in cancer treatment. Angew. Chem. Int. Ed. Engl., 51, 
7203-7207. 
Lenert, P., Goeken, A.J., Ashman, R.F., 2006. Extended sequence preferences for 
oligodeoxyribonucleotide activity. Immunology 117, 474-481. 
Leslie, A.G., Arnott, S., Chandrasekaran, R., Ratliff, R.L., 1980. Polymorphism of DNA 
double helices. J. Mol. Biol. 143, 49-72. 
Li, J., Pei, H., Zhu, B., Liang, L., Wei, M., He, Y., Chen, N., Li, D., Huang, Q., Fan, C., 
2011. Self-assembled multivalent DNA nanostructures for noninvasive intracellular 
delivery of immunostimulatory CpGoligonucleotides. ACS Nano 5, 8783-8789. 
Li, X., Zhang, C., Hao, C., Tian, C., Wang, G., Mao, C., 2012. DNA polyhedra with 
T-linkage. ACS Nano 6, 5138-5142. 
Li, Y., Tseng, Y.D., Kwon, S.Y., D'Espaux, L., Bunch, J.S., McEuen, P.L., Luo, D. 2004. 
Controlled assembly of dendrimer-like DNA. Nat. Mater. 3, 38-42. 
Liu, X., Xu, Y., Yu, T., Clifford, C., Liu, Y., Yan, H., Chang, Y., 2012. A DNA 
nanostructure platform for directed assembly of synthetic vaccines. Nano Lett. 12, 
4254-4259. 
Ma, R.I., Kallenbach, N.R., Sheardy, R.D., Petrillo, M.L., Seeman, N.C., 1986. 
Three-arm nucleic acid junctions are flexible. Nucleic Acids Res. 14, 9745-9753. 
Ma, Z., Li, J., He, F., Wilson, A., Pitt, B., Li, S., 2005. Cationic lipids enhance 
siRNA-mediated interferon response in mice. Biochem. Biophys. Res. Commun. 
330, 755-759. 
Marshall, J. D., Fearon, K., Abbate, C., Subramanian, S., Yee, P., Gregorio, J., Coffman, 
R. L., Van Nest, G., 2003. Identification of a novel CpG DNA class and motif that 
optimally stimulate B cell and plasmacytoid dendritic cell functions. J. Leukocyte 
Biol. 73, 781-792. 
Matsuoka, N., Nishikawa, M., Mohri, K., Rattanakiat, S., Takakura, Y., 2010. Structural 
and immunostimulatory properties of Y-shaped DNA consisting of phosphodiester 
and phosphorothioate oligodeoxynucleotides. J. Control. Release. 148, 311-316. 
Matzinger, P., 1994. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 
12, 991-1045. 
Mohri, K., Nishikawa, M., Takahashi, N., Shiomi, T., Matsuoka, N., Ogawa, K., Endo, 
M., Hidaka, K., Sugiyama, H., Takahashi, Y., Takakura, Y., 2012a. Design and 
development of nanosized DNA assemblies in polypod-like structures as efficient 
vehicles for immunostimulatory CpG motifs to immune cells. ACS Nano 6, 
5931-5940. 
Mohri, K., Takahashi, N., Nishikawa, M., Kusuki, E., Shiomi, T., Takahashi, Y., 
Takakura, Y., 2012b. Increased immunostimulatory activity of polypod-like 
structured DNA by ligation of the terminal loop structures. J. Control. Release. 163, 
285-292. 
Monteith, D.K., Horner, M.J., Gillett, N.A., Butler, M., Geary, R., Burckin, T., 
Ushiro-Watanabe, T., Levin, A.A., 1999. Evaluation of the renal effects of an 
antisense phosphorothioate oligodeoxynucleotide in monkeys. Toxicol Pathol. 27, 
307-317. 
Nayak, S., Lyon, L.A., 2005. Soft nanotechnology with soft nanoparticles. Angew. 
Chem. Int. Ed. Engl. 44, 7686-7708. 
Nishikawa, M., Matono, M., Rattanakiat, S., Matsuoka, N., Takakura, Y., 2008. 
Enhanced immunostimulatory activity of oligodeoxynucleotides by Y-shape 
formation. Immunology 124, 247-255.  
Nishikawa, M., Mizuno, Y., Mohri, K., Matsuoka, N., Rattanakiat, S., Takahashi, Y., 
Funabashi, H., Luo, D., Takakura, Y., 2011. Biodegradable CpG DNA hydrogels for 
sustained delivery of doxorubicin and immunostimulatory signals in tumor-bearing 
mice. Biomaterials 32, 488-494. 
Nishikawa, M., Rattanakiat, S., Takakura, Y., 2010. DNA-based nano-sized systems for 
pharmaceutical and biomedical applications. Adv. Drug Deliv. Rev. 62, 626-632. 
Ozinsky, A., Underhill, D.M., Fontenot, J.D., Hajjar, A.M., Smith, K.D., Wilson, C.B., 
Schroeder, L., Aderem, A., 2000. The repertoire for pattern recognition of pathogens 
by the innate immune system is defined by cooperation between toll-like receptors. 
Proc. Natl. Acad. Sci. U.S.A. 97, 13766-13771. 
Poeck, H., Besch, R., Maihoefer, C., Renn, M., Tormo, D., Morskaya, S.S., Kirschnek, 
S., Gaffal, E., Landsberg, J., Hellmuth, J., Schmidt, A., Anz, D., Bscheider, M., 
Schwerd, T., Berking, C., Bourquin, C., Kalinke, U., Kremmer, E., Kato, H., Akira, 
S., Meyers, R., Häcker, G., Neuenhahn, M., Busch, D., Ruland, J., Rothenfusser, S., 
Prinz, M., Hornung, V., Endres, S., Tüting, T., Hartmann, G., 2008. 
5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against 
melanoma. Nat. Med. 14, 1256-1263. 
Poeck, H., Wagner, M., Battiany, J., Rothenfusser, S., Wellisch, D., Hornung, V., 
Jahrsdorfer, B., Giese, T., Endres, S., Hartmann, G., 2004. Plasmacytoid dendritic 
cells, antigen, and CpG-C license human B cells for plasma cell differentiation and 
immunoglobulin production in the absence of T-cell help. Blood 103, 3058-3064. 
Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S., Medzhitov, R., 2004. 
Recognition of commensal microﬂora by Toll-like receptors is required for intestinal 
homeostasis. Cell 118, 229-241. 
Rankin, R., Pontarollo, R., Ioannou, X., Krieg, A.M., Hecker, R., Babiuk, L.A., van 
Drunen Little-van den Hurk, S., 2001. CpG motif identiﬁcation for veterinary and 
laboratory species demonstrates that sequence recognition is highly conserved. 
Antisense Nucleic Acid Drug Dev. 11, 333-340. 
Rattanakiat, S., Nishikawa, M., Funabashi, H., Luo, D., Takakura, Y., 2009. The 
assembly of a short linear natural cytosine-phosphate-guanine DNA into dendritic 
structures and its effect on immunostimulatory activity. Biomaterials 30, 5701-5706.  
Roh, Y.H., Lee, J.B., Kiatwuthinon, P., Hartman, M.R., Cha, J.J., Um, S.H., Muller, 
D.A., Luo, D., 2011a.  DNAsomes: Multifunctional DNA-based nanocarriers. 
Small 7, 74-78. 
Roh, Y.H., Ruiz, R.C., Peng, S., Lee, J.B., Luo, D., 2011b. Engineering DNA-based 
functional materials. Chem. Soc. Rev. 40, 5730-5744. 
Rothemund, P.W., 2006. Folding DNA to create nanoscale shapes and patterns. Nature 
440, 297-302. 
Sands, H., Gorey-Feret, L.J., Cocuzza, A.J., Hobbs, F.W., Chidester, D., Trainor, G.L., 
1994. Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. 
Comparison of a phosphodiester and a phosphorothioate. Mol. Pharmacol. 45, 
932-943. 
Schlee, M., Roth, A., Hornung, V., Hagmann, C.A., Wimmenauer, V., Barchet, W., Coch, 
C., Janke, M., Mihailovic, A., Wardle, G., Juranek, S., Kato, H., Kawai, T., Poeck, 
H., Fitzgerald, K.A., Takeuchi, O., Akira, S., Tuschl, T., Latz, E., Ludwig, J., 
Hartmann, G., 2009. Recognition of 5' triphosphate by RIG-I helicase requires short 
blunt double-stranded RNA as contained in panhandle of negative-strand virus. 
Immunity 31, 25-34. 
Schmidt, M., Anton, K., Nordhaus, C., Junghans, C., Wittig, B., Worm, M., 2006. 
Cytokine and Ig-production by CG-containing sequences with phosphorodiester 
backbone and dumbbell-shape. Allergy 61, 56-63. 
Schüller, V.J., Heidegger, S., Sandholzer, N., Nickels, P.C., Suhartha, N.A., Endres, S., 
Bourquin, C., Liedl, T., 2011. Cellular immunostimulation by CpG-sequence-coated 
DNA origami structures. ACS Nano 5, 9696-9702. 
Seeman, N.C. 1982. Nucleic acid junctions and lattices. J. Theor. Biol. 99, 237-247. 
Seeman, N.C., 2010. Nanomaterials based on DNA. Annu. Rev. Biochem. 79, 65-87. 
Shinagawa, H., Iwasaki, H., 1995. Molecular mechanisms of Holliday junction 
processing in Escherichia coli. Adv. Biophys. 31, 49-65. 
Simmel, F.C., 2012. DNA-based assembly lines and nanofactories. Curr. Opin. 
Biotechnol. 23, 516-521. 
Smolarczyk, R., Cichoń, T., Sochanik, A., Szala, S., 2005. Negligible induction of 
IFN-gamma, IL-12 and TNF-alpha by DNA-PEI 750 kDa/albumin complexes. 
Cytokine 29, 283-287. 
Smyth, M.J., Taniguchi, M., Street, S.E., 2000. The anti-tumor activity of IL-12: 
mechanisms of innate immunity that are model and dose dependent. J. Immunol. 
165, 2665-2670. 
Stein, C.A., Subasinghe, C., Shinozuka, K., Cohen, J.S., 1988. Physicochemical 
properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. 16, 
3209-3221. 
Swiecki, M., McCartney, S.A., Wang, Y., Colonna, M., 2011. TLR7/9 versus 
TLR3/MDA5 signaling during virus infections and diabetes. J. Leukoc. Biol. 90, 
691-701. 
Takakura, Y., Nishikawa, M., Yamashita, F., Hashida, M., 2001. Development of gene 
drug delivery systems based on pharmacokinetic studies. Eur. J. Pharm. Sci. 13, 
71-76. 
Takaoka, A., Wang, Z., Choi, M.K., Yanai, H., Negishi, H., Ban, T., Lu, Y., Miyagishi, 
M., Kodama, T., Honda, K., Ohba, Y., Taniguchi, T., 2007. DAI (DLM-1/ZBP1) is a 
cytosolic DNA sensor and an activator of innate immune response. Nature 448, 
501-505. 
Tokunaga, T., Yamamoto, S., Namba, K., 1988. A synthetic single-stranded DNA, 
poly(dG,dC), induces interferon-alpha/beta and -gamma, augments natural killer 
activity, and suppresses tumor growth. Jpn J. Cancer. Res. 79, 682-686. 
Tomita, N., Ogihara, T., Morishita, R., 2003. Transcription factors as molecular targets: 
molecular mechanisms of decoy ODN and their design. Curr. Drug Targets 4, 
603-608. 
Tsai, C.Y., Lu, S.L., Hu, C.W., Yeh, C.S., Lee, G.B., Lei, H.Y., 2012. Size-dependent 
attenuation of TLR9 signaling by gold nanoparticles in macrophages. J. Immunol. 
188, 68-76. 
Uematsu, S., Akira, S., 2007. Toll-like receptors and Type I interferons. J. Biol. Chem. 
282, 15319-15323. 
Um, S.H., Lee, J.B., Park, N., Kwon, S.Y., Umbach, C.C., Luo, D., 2006. 
Enzyme-catalysed assembly of DNA hydrogel. Nat. Mater. 5, 797-801. 
Uno, S., Nishikawa, M., Mohri, K., Umeki, Y., Matsuzaki, N., Takahashi, Y., Fujita, H., 
Kadowaki, N., Takakura, Y., Efficient delivery of immunostimulatory DNA to 
mouse and human immune cells through the construction of polypod-like structured 
DNA. Nanomedicine, in press. 
Vollmer, J., Weeratna, R., Payette, P., Jurk, M., Schetter, C., Laucht, M., Wader, T., Tluk, 
S., Liu, M., Davis, H. L., Krieg, A. M., 2004. Characterization of three CpG 
oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur. J. 
Immunol. 34, 251-262. 
Wagner, R.W., 1994. Gene inhibition using antisense oligodeoxynucleotides. Nature 
372, 333–335. 
Wang, Z., Choi, M.K., Ban, T., Yanai, H., Negishi, H., Lu, Y., Tamura, T., Takaoka, A., 
Nishikura, K., Taniguchi, T., 2008. Regulation of innate immune responses by DAI 
(DLM-1/ZBP1) and other DNA-sensing molecules. Proc. Natl. Acad. Sci. U.S.A. 
105, 5477-5482. 
Watson, J.D., Crick, F.H., 1974. Molecular structure of nucleic acids: a structure for 
deoxyribose nucleic acid. Nature 248, 765. 
Wu, D.Y., Wallace, R.B., 1989. Specificity of the nick-closing activity of bacteriophage 
T4 DNA ligase. Gene. 76, 245-254. 
Yang, L., Wu, X., Wan, M., Yu, Y., Yu, Y., Wang, L., 2013. CpG oligodeoxynucleotides 
with double stem-loops show strong immunostimulatory activity. Int. 
Immunopharmacol. 15, 89-96. 
Yi, A.K., Chang, M., Peckham, D.W., Krieg, A.M., Ashman, R.F., 1998. CpG 
oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis 
and promote cell cycle entry. J. Immunol. 160, 5898-5906. 
Yi, A.K., Klinman, D.M., Martin, T.L., Matson, S., Krieg, A.M., 1996. Rapid immune 
activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription 
through anantioxidant-sensitive pathway. J. Immunol. 157, 5394-5402. 
Zhang, C., Ko, S.H., Su, M., Leng, Y., Ribbe, A.E., Jiang, W., Mao, C., 2009. Symmetry 
controls the face geometry of DNA polyhedra. J. Am. Chem. Soc. 131, 1413-1415. 
Zhang, C., Su, M., He, Y., Leng, Y., Ribbe, A.E., Wang, G., Jiang, W., Mao, C., 2010. 
Exterior modification of a DNA tetrahedron. Chem. Commun. 46, 6792-6794. 
Zhang, C., Su, M., He, Y., Zhao, X., Fang, P.A., Ribbe, A.E., Jiang, W., Mao, C., 2008. 
Conformational flexibility facilitates self-assembly of complex DNA nanostructures. 
Proc Natl Acad Sci U.S.A. 105, 10665-10669. 
Zhao, Y.X., Shaw, A., Zeng, X., Benson, E., Nyström, A.M., Högberg, B., 2012. DNA 
origami delivery system for cancer therapy with tunable release properties. ACS 





Figure 1. DNA ligase-catalyzed reaction and schematic representations of DNA 
assemblies. In most cases, double-strand formation between two DNA molecules acts as 
the driving force for the formation of DNA assemblies. (A) Two double-stranded DNA 
molecules can be connected by hybridization through the sticky ends (5’-GTCA-3’ and 
5’-TGAC-3’ in this case). The nick between the two double-stranded DNA molecules 
can be enzymatically ligated, to produce one double-stranded DNA. (B) The sequence 
and planar presentation of Y-DNA and X-DNA. (C) Schematic representations of a 
variety of DNA assemblies. Tetrahedral DNA (left) (He et al., 2008), hexahedral DNA 
(middle) (Chen and Seeman, 1991), and icosahedral DNA (right) (He et al., 2010). 
 
Figure 2. DNA- or RNA-mediated stimulation of innate immunity. DNA or RNA is 
taken up by immune cells via endocytosis. In endosomes, TLR3, TLR7/8, or TLR9 
recognizes double-stranded RNA, single-stranded RNA, or CpG DNA, respectively. 
RIG-I or DAI recognizes single-stranded triphosphate RNA or double-stranded DNA, 
respectively, in the cytoplasm. These interactions activate the NF-kB or IRFs, resulting 
in the production of proinﬂammatory cytokines and IFNs.  
 
Figure 3. Schematic illustration of DNA assemblies for the delivery of CpG DNA. (A) 
Polypod-like DNA (polypodna) with three (tripodna) to twelve (dodecapodna) pods. (B) 
First to third generations (G1 to G3) of dendrimer-like DNA (DL-DNA). (C) DNA 







Table 1. DNA nanostructures used for drug delivery 
DNA 
nanostructure 
Cargo Size Advantage Reference 
Tetrahedral DNA Antisense DNA ∼7 nm High cellular uptake Keum et al. 
(2011) 
Tetrahedral DNA siRNA ∼29 nm Long blood 
circulation, tumor 
targeting 
Lee et al. 
(2012) 
DNAsome siRNA, Doxorubicin 110-1,100 nm High loading 
capacity and 
efficiency 
Roh et al. 
(2011a) 
DNA hydrogel Insulin - Sustained release Um et al. 
(2006) 
DNA triangle Doxorubicin - High loading 
efficiency 




Doxorubicin 380 nm High loading 
efficiency 




Doxorubicin 138 nm 13 nm High loading 
efficiency 






35 nm 35 nm 
45 nm 
Sensing cell surface  Douglas et al. 
(2012) 
 
 
